Charles River Laboratories International Profit Margin

The latest profit margin for CRL is -5.96% as of June 2026. That compares with -1.65% in the prior-year period — down 262.4% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside Charles River Laboratories International's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRL's profit margin moved from -1.65% to -5.96% — a 262.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Charles River Laboratories International's valuation or profitability profile.

Against Healthcare companies, CRL currently prints -5.96% for profit margin, while the sector average sits near 14.41%. That is roughly 141.4% below the sector mean. Large gaps often invite a closer look at Charles River Laboratories International's growth, margins, and balance sheet.

Profit Margin shows how effectively Charles River Laboratories International converts resources into returns. At -5.96%, CRL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1.65% in the prior-year period — down 262.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CRL's profit margin (-5.96%), review year-over-year change from -1.65%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.